Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CRDF

+ Watchlist+ Portfolio

Cardiff Oncology, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.85
52-Week Range
$0.71 – $3.31
Market Cap
$65.27M
P/E (TTM)
—
EPS (TTM)
-0.54
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.26
PEG Ratio
—
Return on Equity
-94.08%
Return on Assets
-46.73%
Gross Margin
0.00%
Operating Margin
-8320.08%
Profit Margin
0.00%
Current Ratio
3.30
Debt/Equity
0.02
Total Debt
$457.00K
Free Cash Flow
$-24.30M
Revenue Growth
-14.10%
Earnings Growth
—
Enterprise Value
$22.54M

Market Snapshot

About

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel therapies for the treatment of cancer. Headquartered in San Diego, California, the company's lead product candidate is onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor being evaluated in combination with standard-of-care chemotherapy across multiple cancer types. Cardiff is conducting clinical trials in colorectal cancer, KRAS-mutated metastatic colorectal cancer, and other solid tumors. The company's research focuses on targeting cancer cell proliferation and resistance mechanisms.